Ligand Out-Licenses China Rights for Three Liver Products to Nucorion

San Diego's Ligand Pharma  formed a new company, Nucorion Pharma, that will develop three preclinical Ligand programs in China. Each of the programs use Ligand’s LTP (Liver Targeting Prodrug) technology. Nucorion, which is backed by Silver River Investors of Hong Kong, will also develop drug candidates licensed directly from Ohio State University. The company will develop anti-cancer and anti-viral products with an initial target of the China market. Nucorion raised $5 million in a Series A led by Silver River; Ligand invested $1 million and will own less than 20% of Nucorion. More details.... Stock Symbol: (NSDQ: LGND) Share this with colleagues: // //